EMBL

Quality Assistance S.A. is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products.

We assist our clients from candidate selection, through non-clinical and clinical studies, to marketing authorisation, using our state-of-the-art, product-dedicated expertise in analytical sciences.

For each customer and each project, we design customised solutions, define analytical protocols, develop and validate specific new analytical methods and perform characterisation, stability, pharmacokinetic, biomarker and immunogenicity studies as well as batch release testing, in order to evaluate the Quality, Safety and Efficacy of the given drugs.

Quality Assistance S.A. is an expert for the development of:
- Biologics (monoclonal antibodies, ADCs, proteins)
- New Chemical Entities, oligonucleotides, peptides
- Nanomedicine products
- Vaccines
- Cell-Based and Gene Therapy Medicinal Products

The company holds a unique position on the market with:
All its laboratories on one site (Donstiennes, Belgium)
- Bioanalysis (PK/TK/Immuno)
- Bioassays
- Biochemistry
- Chromatography
- Elemental Impurities
- Mass Spectrometry
- Microbiology
- Molecular Biology
- Protein Characterisation
200 highly qualified professionals
more than 35 years’ expertise at the forefront of analytical sciences.

Our core competencies are:
QUALITY (CMC)
- Development and validation of analytical methods
- Characterisation
- Stability studies
- Batch (release) testing
SAFETY/EFFICACY (Bioanalysis)
- Development and validation of bioanalytical methods
- PK/TK studies
- Immunogenicity studies
- Biomarker studies

The Quality Assistance environment is GMP, GLP and GCLP/GCP compliant.

Visit www.quality-assistance.com for more information

Addgene is a nonprofit plasmid repository located in Watertown, Massachusetts. Addgene’s mission is to accelerate research and discovery by improving access to useful research materials and information. Addgene facilitates the sharing of high-quality scientific materials, research reproducibility, and open science by archiving and distributing DNA-based research reagents and associated data to scientists worldwide. Addgene’s repository contains over 70,000 plasmids, including special collections on CRISPR, fluorescent proteins, chemogenetics, optogenetics, and viral plasmids. All plasmids in Addgene’s repository were deposited by your scientific colleagues from around the world. There is no cost for scientists to deposit plasmids, which saves time and money associated with shipping plasmids themselves. All plasmids are fully sequenced for validation and sequencing data is openly available. Addgene also provides ready-to-use AAV and lentiviral preparations of commonly requested plasmids as a service to scientists. Addgene offers free online educational resources and protocols about molecular biology topics such as common vector backbones, cloning, CRISPR, AAV and lentivirus production, and science careers. These resources include the Addgene blog, eBooks, guides, videos, and a podcast series.

Advanced Molecular Technologies Pty Ltd (AMT) is a contract research organisation (CRO) established in 2005, specialising in medicinal chemistry and custom organic synthesis. The provided services involve the synthesis of target molecules, the manufacturing (larger-scale) of chemical materials, analytical chemistry, chemical method development and optimisation, drug discovery and synthetic organic research.

AMT is also a manufacturer and supplier of chemicals in Victoria, Australia, distributing specialty products to partners, institutions and companies worldwide.

AMT has extensive experience in organoboron, organosilicon, PEG-linkers and fluorophore technology, with many of these discrete molecules available for purchase on their website. More recently, AMT is spinning-out its own initiatives through novel technology developed within the pharmaceutical and veterinary industries.

Equipped with a 400 MHz NMR machine, HPLC, GC, FT-IR and several other analytical pieces of equipment, AMT also readily provides analytical services to the chemical industry.

ATDBio is a UK-based SME with laboratories in Southampton and Oxford, specialising in the synthesis of highly pure DNA oligonucleotides.

ATDBio makes oligonucleotides that are used in academic and commercial research in the fields of genetics, genomics, molecular biology, biochemistry, biotechnology and nanotechnology, including some of the world's largest biotech companies. We supply a wide range of custom-made unmodified and chemically modified oligonucleotides for small and large scale applications. Collectively, we have well over 50 years' experience in nucleic acids chemistry and oligo synthesis, and we are at the forefront of nucleic acids research.

ATDBio was founded in 2005 by Prof. Tom Brown, Professor of Nucleic Acids Chemistry at the University of Oxford and one of the world's leading nucleic acid chemists, and Dr Dorcas Brown, an expert in oligonucleotide synthesis.

ATDBio has recently heavily invested in increasing its R&D capabilities by expanding both the main site in Southampton and developing a new dedicated R&D site at the Oxford Science Park, including new equipment for the synthesis, analysis and purification of oligonucleotides.

Biotheranostics, Inc., is a leader in helping physicians improve the care of cancer patients, offering a suite of proprietary genomics-based molecular diagnostics that allow treatment to be tailored to individual patients.

The company’s CancerTYPE ID® is the most rigorously validated gene expression test for metastatic patients with diagnostic ambiguity, helping physicians determine optimal site-directed treatment regimens with the goal of improving patient outcomes.

Its Breast Cancer IndexSM helps oncologists make difficult decisions about extended endocrine therapy for ER+ breast cancer patients based on its unique ability to predict risk of late disease recurrence and identify which patients are likely to benefit from continuing therapy beyond five years.

Biotheranostics operates a CLIA-certified, CAP-accredited diagnostic laboratory in San Diego. Learn more at biotheranostics.com.